All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Steven Z. Pavletic, National Cancer Institute, Bethesda, US, about the ROCKstar study. We asked, What patients with chronic GvHD benefit most from belumosudil?
More effective and safe treatments are needed for chronic GvHD, one of the major and most difficult complications of allogeneic hematopoietic stem cell transplantation. In this video, Pavletic discusses the results of the phase II ROCKstar study, evaluating belumosudil in patients with moderate to severe chronic GvHD who failed two or more prior lines of therapy.
Read a summary of the phase II ROCKstar study, here.
Subscribe to get the best content related to GvHD delivered to your inbox